Skip to main content

Table 2 Clinical characteristics grouped by different SUV and EBV DNA level

From: Maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography compared with Epstein-Barr virus DNA as prognostic indicators in de novo metastatic nasopharyngeal carcinoma patients

  SUVmax-T n(%) SUVmax-N n(%) SUVmax-M n(%) EBV DNA n(%)
Characteristic    P value    P value    P value    P value
Total 175 78   104 149   77 176   95 158  
Gender
 Male 148(84.6%) 68(87.2%) 0.701 88(84.6%) 128(85.9%) 0.857 67(87.0%) 149(84.7%) 0.702 78(82.1%) 138(87.3%) 0.274
 Female 27(18.2%) 10(12.8%)   16(15.4%) 21(14.1%)   10(13.0%) 27(15.3%)   17(17.9%) 20(12.7%)  
Age (years)
  ≤ 47 88(50.3%) 45(57.7%) 0.340 49(47.1%) 84(56.4%) 0.161 42(54.5%) 91(51.7%) 0.684 50(52.6%) 83(52.5%) > 0.999
  > 47 87(49.7%) 33(42.3%)   55(52.9%) 65(43.6%)   35(45.5%) 85(48.3%)   45(47.4%) 75(47.5%)  
T stage #
 T1 10(5.7%) 2(2.6%) 0.089 7(6.7%) 5(3.4%) 0.187 4(5.2%) 8(4.5%) 0.984 5(5.3%) 7(4.4%) 0.008
 T2 19(10.9%) 3(3.8%)   7(6.7%) 15(10.1%)   7(9.1%) 15(8.5%)   15(15.8%) 7(4.4%)  
 T3 93(53.1%) 40(51.3%)   49(47.1%) 84(56.4%)   39(50.6%) 94(53.4%)   50(52.6%) 83(52.5%)  
 T4 53(30.3%) 33(42.3%)   41(39.4%) 45(30.2%)   27(35.1%) 59(33.5%)   25(26.3%) 61(38.6%)  
N stage #
 N0 4(2.3%) 0(0.0%) 0.525* 4(3.8%) 0(0.0%) < 0.001* 2(2.6%) 2(1.1%) 0.332* 4(4.2%) 0(0.0%) 0.002*
 N1 21(12.0%) 7(9.0%)   18(17.3%) 10(6.7%)   8(10.4%) 20(11.4%)   13(13.7%) 15(9.5%)  
 N2 66(37.7%) 28(35.9%)   42(40.4%) 52(34.9%)   34(44.2%) 60(34.1%)   42(44.2%) 52(32.9%)  
 N3 84(48.0%) 43(55.1%)   40(38.5%) 87(58.4%)   33(42.9%) 94(53.4%)   36(37.9%) 91(57.6%)  
Metastatic site sites
 Bone 87(49.7%) 29(37.2%) 0.056 58(55.8%) 58(38.9%) 0.005 31(40.3%) 85(48.3%) < 0.001 47(49.5%) 69(43.7%) 0.001
 Lung 20(11.4%) 8(10.3%)   13(12.5%) 15(10.1%)   13(16.9%) 15(8.5%)   17(17.9%) 11(7.0%)  
 Liver 8(4.6%) 6(7.7%)   5(4.8%) 9(6.0%)   5(6.5%) 9(5.1%)   5(5.3%) 9(5.7%)  
 Distant nodes 18(10.3%) 4(5.1%)   11(10.6%) 11(7.4%)   15(19.5%) 7(4.0%)   11(11.6%) 11(7.0%)  
 Multiple sites 42(24.0%) 31(39.7%)   17(16.3%) 56(37.6%)   13(16.9%) 60(34.1%)   15(15.8%) 58(36.7%)  
LRRT use
 No 60(34.3%) 29(37.7%) 0.668 34(33.3%) 55(36.9%) 0.592 20(26.0%) 69(39.4%) 0.045 28(29.5%) 61(38.9%) 0.137
 Yes 115(65.7%) 48(62.3%)   69(67.0%) 94(63.1%)   57(74.0%) 106(60.6%)   67(70.5%) 96(61.1%)  
  1. Abbreviations: LRRT locoregional radiotherapy
  2. According to the 8th edition of the UICC/AJCC staging system
  3. The P value was calculated with the Pearson χ2 test or Fisher’s exact test (*)
  4. Bold data referred to statistical significance (P < 0.05)